Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Allarity Therapeutics is raising $40,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Steve Carchedi played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Allarity Therapeutics

Allarity Therapeutics is a late clinical-stage, precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Allarity’s clinical program includes six anti-cancer assets in mid- to late-stage clinical development. Our programs and partnerships leverage our proprietary, highly accurate Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. Our DRP technology has been broadly validated across an extensive array of therapies and tumor types with a high degree of accuracy for matching the right patient to the right drug. By identifying those patients who will and who will not respond, the DRP companion diagnostics have the potential to transform cancer therapeutic development across many indications by increasing clinical success rates with trials involving a fewer number of patients, and improve patient outcomes by matching them to the right drug. Publicly traded on the NASDAQ First North, Allarity Therapeutics (ALLR) is headquartered in Horsholm, Denmark, with US operations, and is committed to enhancing patient outcomes through improved decision-making and personalized cancer care.

To learn more about Allarity Therapeutics, visit http://allarity.com/

Contact:
Steve Carchedi, Chief Executive Officer
401-426-4664
scarchedi@allarity.com
https://www.linkedin.com/in/stevecarchedir/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved